{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:12Z","timestamp":1787844192995,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Atorvastatin has a longer duration of action than other hydroxymethylglutaryl coenzyme A reductase inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective was to evaluate the efficacy of alternate day vs. daily dosing of atorvastatin for the treatment of hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      In this prospective, open label, crossover study, 40 patients with plasma low-density cholesterol (LDL-C) of more than 130 mg\/dl and total cholesterol (TC) more than 200 mg\/dl were recruited. After baseline tests, they were randomly allocated to two groups. Group A received 20 mg atorvastatin on alternate days and group B received 20 mg atorvastatin daily for 12 weeks. After 4 weeks of washout period, the groups were crossed over to the other treatment regimen for another 12 weeks. Fasting plasma lipid profile and serum alanine transaminase (ALT) and aspartate transaminase (AST) were measured for both groups at 6\n                      <jats:sup>th<\/jats:sup>\n                      , 12\n                      <jats:sup>th<\/jats:sup>\n                      , 16\n                      <jats:sup>th<\/jats:sup>\n                      , 22\n                      <jats:sup>nd<\/jats:sup>\n                      , and 28\n                      <jats:sup>th<\/jats:sup>\n                      weeks. Results were pooled across the periods and data between the two groups were compared using unpaired\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 40 enrolled subjects, 38 completed the study. Both treatment regimens significantly reduced LDL-C and TC compared to baseline. There was no statistically significant difference between the two groups in terms of reduction of plasma LDL-C and TC at 6 and 12 weeks of treatment. Both the regimens were well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Alternate-day treatment with atorvastatin is comparable in efficacy and safety to the established daily treatment regimen, thus being a cost effective alternative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0253-7613.96326","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T14:28:31Z","timestamp":1337264911000},"page":"362-365","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of alternate-day versus everyday dosing of atorvastatin"],"prefix":"10.4103","volume":"44","author":[{"given":"Sushobhan","family":"Pramanik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asoke Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanta Kumar","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mainak","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchal Kumar","family":"Dalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20260529","first-page":"312","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"93","author":"Mukherjee","year":"1995","journal-title":"J Indian Med Assoc"},{"key":"R2-15-20260529","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/hrt.2007.132951","article-title":"Epidemiology and causation of coronary heart disease and stroke in India","volume":"94","author":"Gupta","year":"2008","journal-title":"Heart"},{"key":"R3-15-20260529","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archinte.161.7.949","article-title":"Applicability of Cholesterol-lowering primary prevention trials to a General population: The Framingham Heart Study","volume":"161","author":"Lloyd-Jones","year":"2001","journal-title":"Arch Intern Med"},{"key":"R4-15-20260529","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R5-15-20260529","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: A double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"R6-15-20260529","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R8-15-20260529","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennern\u00e4s","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"R10-15-20260529","first-page":"404","article-title":"Ambiguous drug pricing: A physician's dilemma","volume":"30","author":"Roy","year":"1998","journal-title":"Indian J Pharmacol"},{"key":"R11-15-20260529","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/0253-7613.77344","article-title":"A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India","volume":"43","author":"Singal","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"R14-15-20260529","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk","year":"2005","journal-title":"Prev Cardiol"},{"key":"R15-15-20260529","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/107424840300800205","article-title":"Efficacy of Alternate-Day Dosing Versus Daily Dosing of Atorvastatin","volume":"8","author":"Ebrahimi","year":"2003","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R16-15-20260529","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00592-006-0216-4","article-title":"Alternate-day dosing of atorvastatin: Effects in treating type 2 diabetic patients with dyslipidaemia","volume":"43","author":"Ferrer-Garc\u00eda","year":"2006","journal-title":"Acta Diabetol"},{"key":"R17-15-20260529","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1345\/aph.1E134","article-title":"Comparing hyperlipidemia control with daily versus twice-weekly simvastatin","volume":"38","author":"Mangin","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R19-15-20260529","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2125.1979.tb05903.x","article-title":"The two-period crossover clinical trial","volume":"8","author":"Hills","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"R20-15-20260529","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2307\/2530496","article-title":"The crossover experiment for clinical trials","volume":"36","author":"Brown","year":"1980","journal-title":"Biometrics"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363791-201244030-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:13:45Z","timestamp":1787843625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363791-201244030-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4103\/0253-7613.96326","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}